<DOC>
	<DOCNO>NCT01312467</DOCNO>
	<brief_summary>The purpose study find whether METFORMIN decrease protein marker colorectal tissue . This phase IIA study pharmacodynamics , safety tolerability Metformin decrease colorectal mucosa patient history colorectal adenoma past 3 year BMI &gt; = 30 , decimal round near whole integer . Metformin potential chemopreventive agent inhibition relevant molecular pathway involve human colorectal carcinogenesis .</brief_summary>
	<brief_title>A Trial Metformin Colorectal Cancer Risk Reduction Among Patients With History Colorectal Adenomas Elevated Body Mass Index</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 12-week intervention oral metformin ( metformin hydrochloride ) treatment among obese patient history colorectal adenoma result least 35 % decrease colorectal mucosa activate pS6serine235 baseline assess via immunostaining . SECONDARY OBJECTIVES : I . To assess effect metformin additional relevant biomarkers serum : metformin level ; fast insulin-like growth factor ( IGF ) -1 , insulin-like growth factor bind protein ( IGFBP ) -1 , IGFBP-3 ; fast leptin ; fast Adiponectin ; fast 2 hour post-prandial insulin glucose . II . To examine correlation among biomarkers ( serum , tissue ) . III . To assess independent effect treatment biomarker , use multivariate regression model account clinical biomarker data . IV . To document safety tolerability metformin study population . TERTIARY OBJECTIVES : I . To assess effect metformin additional relevant biomarkers tissue via immunostaining . This include effect level colorectal mucosa proliferation estimate : phosphorylated AMPK ( pAMPK ) , phosphorylated AKTserine 473 ( pAKT ) , phosphorylated mTOR , phosphorylated insulin receptor ( pIR ) , phosphorylated IGF-1 ( pIGF-1 ) receptor , Ki-67 . II . To cross-validate immunostaining result Western blot experiment subset consecutive patient follow endpoint : phosphorylated S6serine235 ( pS6serine235 ) , phosphorylated AMPK ( pAMPK ) , phosphorylated AKTserine 473 ( pAKT ) , phosphorylated mTOR , phosphorylated insulin receptor ( pIR ) , phosphorylated IGF-1 ( pIGF-1 ) receptor , Ki-67 . OUTLINE : Patients receive metformin hydrochloride orally ( PO ) daily ( QD ) week 1 twice daily ( BID ) week 2-12 . Treatment continue 12 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow 4 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Adenomatous Polyps</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>History prior colorectal adenoma within past 3 year ; patient adenomas endoscopically remove eligible ; documentation colorectal adenoma must determine via review pathology report Body mass index ( BMI ) &gt; = 30 ; round near whole integer Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Leukocytes ≥ 3,000/μL ( &gt; = 2,500/μL AfricanAmerican participant ) Absolute neutrophil count &gt; = 1,500/μL ( &gt; = 1,000/μL AfricanAmerican participant ) Platelets &gt; = 100,000/μL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 1.5 X institutional upper limit normal ( ULN ) Creatinine within normal institutional limit Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation A serum pregnancy test must perform negative woman childbearing potential within 2 week prior start treatment Ability understand willingness sign write informed consent document History colorectal cancer cancer ( ) ( except nonmelanoma skin cancer ) within last 3 year Family history hereditary intestinal polyp disorder ( e.g. , familial adenomatous polyposis [ FAP ] , hereditary nonpolyposis colorectal cancer [ HNPCC ] , PutzJegher 's disease ) Participants diabetes History vitamin B12 deficiency megaloblastic anemia History lactic acidosis Diet medication weight loss Diseases associate weight loss : anorexia , bulimia , nausea Treatment medication may increase metformin level : cationic drug , e.g. , digoxin , amiloride , procainamide , trimethoprim , vancomycin , triamterene , morphine Treatment oral hypoglycemic agent Participants undergone full bowel resection , ablation local therapy Participants may receive investigational agent History allergic reaction attribute compound similar chemical biologic composition metformin Participants human immunodeficiency virus ( HIV ) , cirrhosis cause , NASH ( nonalcoholic steatohepatitis ) , hepatitis ( autoimmune infectious ) Kidney disease renal insufficiency ( define serum creatinine &gt; 1.4 mg/dL female &gt; 1.5 mg/dL male ) Metabolic acidosis , acute chronic , include ketoacidosis Uncontrolled intercurrent illness include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Renal failure Hepatic failure Sepsis Hypoxia Pregnant breastfeed woman exclude Participants anticipate elective surgery study period Contraindication colonoscopy/flexible sigmoidoscopy Participants may use metformin , cimetidine ( Tagament ) furosemide ( Lasix ) , nifedipine ( Cardizem ) , Ranitidine ( Zinetac Zantac ) , digoxin ( Lanoxin ) , Quinidine drug contraindicate use metformin Chronic alcohol use history alcohol abuse Participants medical psychosocial condition , opinion investigator , could jeopardize participation compliance study criterion Participants regularly use aspirin ( ASA ) , nonsteroidal antiinflammatory drug ( NSAIDs ) , calcium , cyclooxygenase ( Cox ) 2 inhibitor eligible enrollment ; however , patient use aspirin 81 mg daily , aspirin 325 mg , NSAIDs , calcium , Cox2 inhibitor frequency &lt; 10 time per month eligible</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>